Last reviewed · How we verify

NCT02806154: FRACTION

Frailty and Body Composition in the Elderly Cancer Patients Treated With Chemotherapy

Completed Last updated 19 July 2023
What this trial tests

trial testing DEXA in Cancer in 144 participants. Completed in 29 March 2023.

Timeline
27 March 2017
Primary endpoint
29 March 2023
29 March 2023

Quick facts

Lead sponsorUniversity Hospital, Toulouse
StatusCompleted
Study typeOBSERVATIONAL
Enrollment144
Start date27 March 2017
Primary completion29 March 2023
Estimated completion29 March 2023
Sites8 locations across France

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Toulouse

Who can join

70 and older, any sex, with Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators could hypothesize that age-related changes in body composition parameters play a role in the variable tolerance to chemotherapy in the elderly.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Low lean mass and chemotherapy toxicity risk in the elderly: the Fraction study protocol.
    Steinmeyer Z, Gérard S, Filleron T, Lozano S, et al · · 2019 · cited 6× · PMID 31775667 · DOI 10.1186/s12885-019-6377-7

Verify or expand the search:

Other trials of DEXA

Trials testing the same drug.

Other recruiting trials for Cancer

Currently open trials in the same condition.

Other University Hospital, Toulouse trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02806154.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing